Table II.
Analysis of GLII levels and other clinicopathological variables for patient survival.
| Expression analysis | Survival analysis | ||||
|---|---|---|---|---|---|
| Clinicopathological variable | GLI1-high, n (%) | GLI1-low, n (%) | P-valuea | MeanPFSd, months | P-valueb |
| Sex | |||||
| Male | 6 (25.0) | 18 (75.0) | >0.999 | 5.2 | 0.575 |
| Female | 3 (23.1) | 10 (76.9) | 7.1 | ||
| Smoker | |||||
| Yes | 6 (35.3) | 11 (64.7) | 0.251 | 7.3 | 0.873 |
| No | 3 (15.0) | 17 (85.0) | 4.8 | ||
| Pathological subtypec | |||||
| Adeno | 4 (16.0) | 21 (84.0) | 0.034 | 7.0 | 0.236 |
| Squamous | 5 (55.6) | 4 (44.4) | 4.5 | ||
| Age, years | |||||
| <60 | 4 (21.1) | 15 (78.9) | 0.714 | 5.7 | 0.872 |
| >60 | 5 (27.8) | 13 (72.2) | 7.2 | ||
| Stage | |||||
| III | 3 (42.9) | 4 (57.1) | 0.327 | 3.8 | 0.241 |
| IV | 6 (20.0) | 24 (80.0) | 7.0 | ||
a
Fisher exact test.
b
Log-rank test.
c
Three cases were not included in the two pathological subtypes listed in the table. Two cases were adenosquamous carcinomas and one was a large cell neuroendocrine carcinoma.
d
PFS, progression-free survival.